---
schema_version: "secwatch.filing_event.v1"
accession: "0000896622-22-000011"
form_type: "8-K"
ticker: "ATR"
cik: "0000896622"
company_name: "APTARGROUP, INC."
filed_at: "2022-04-28T23:59:59+00:00"
generated_at: "2026-06-26T03:48:40.490026+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AptarGroup Q1 revenue up 9% to $845M; adjusted EPS down to $0.96 from $1.05

## Summary
- Reported sales $845M (+9% YoY); core sales +13% with double-digit growth in all segments.
- Adjusted EPS $0.96 vs $1.05 prior year; reported EPS $0.93 included $0.19 unrealized gain in prior year.
- Pharma core sales +13%; demand for allergic rhinitis and asthma devices recovering.
- Q2 2022 adjusted EPS guidance $0.92-$1.02; midpoint +14% on constant-currency basis.
- Dividend maintained at $0.38/share; $16M share repurchases in Q1, $184M remaining authorization.

## SEC filing metadata
- accession: 0000896622-22-000011
- form_type: 8-K
- ticker: ATR
- cik: 0000896622
- company_name: APTARGROUP, INC.
- filed_at: 2022-04-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/896622/000089662222000011/0000896622-22-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/896622/000089662222000011/atr-20220428.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000896622-22-000011
- JSON: https://secwatch.observer/filing/0000896622-22-000011.json
- Plain text: https://secwatch.observer/filing/0000896622-22-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.